RE: 202011 Jan 2020 10:50
Bothwell, that's as maybe, but only speculative by our management.
Given what has transpired with respect to EU sales, I do wonder if sales in either of the two regions will be as they predict. Although EU sales were expected to be lackluster, they were certainly not expected to be the disaster they have been (Remember JMs preamble of the 2018 year end results..."disappointed RPG didn't make a profit". For RPG to make a profit, they would have needed 28mill USD just to brake even given the yearly write down). The guy and it would appear our management have their heads well and truly stuck up eachothers asses or in the clouds. Why wasn't some of JG's salary used to do a bit of market research to back up the continuous EU sales predictions given in the presentations....last one being in March 2019 and that's after many months of disastrous sales. god knows what goes through their non-professional brains.
It seems to me that although there is this constant "one in 4 sufferers" etc etc, neither RPG or Recordati did any proper market research as to how many of these one in 4 would come out of the woodwork and visit a doctor and although there is advertising in the US, it will have no impact if sufferers are too embarrassed to seek help.
The FDA gov website still indicates the 31st Dec as a finish date for the phase 2 study, why has this not been updated to indicate it has finished or even revised to indicate a later date (It was originally the end of March)? JG is now using the so called "closed period" to not provide any information, but it certainly wont stop him from advising of another profit warning. I really think he has no incentive and never has. The longer it takes, the more he makes (I'm a poet and I don't know it)....LOL